权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Investigation on a cooperative development of stratergy on curative treatment of leukemia with Federal Republic of Germany

与德意志联邦共和国合作制定白血病治疗策略的探讨

基本信息

批准号：
02042003
负责人：
OHNO Ryuzo
金额：
$ 2.56万
依托单位：
Nagoya University
依托单位国家：
日本
项目类别：
Grant-in-Aid for international Scientific Research
财政年份：
1990
资助国家：
日本
起止时间：
1990 至 1991
项目状态：
已结题

来源：
https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-02042003/
关键词：
Federal Republic of Germany Leukemia Cooperative study University of Munster Hannover Medical School Chemotherapy FAB classification

项目摘要

Federal Republic of Germany (FRG) now leads the world in the field of leukemia therapy. The strategy of curative intensive therapy and the number of patients involved in their nation-wide clinical studies surpass those of U. S. A or other parts of Europe. The rapid rise of quality and quantity of their clinical studies of leukemia has derived from government-supported funds for the war against cancer which started in 1979. Their concept was characterized by the emphases on the role of biostatistics in planning of protocols and the analysis of data, and 5 biostatistc centers were established throughout FRG. Unlike in U. S. A, , FRG government did not support to establish oncology groups, but formed project teams on each cancer. Each project team receives approximately 20 to 50 x 10^6 Yen per year for about 5 to 7 years. For example, in the fields of adult leukemia, there are 3 project teams ; acute myeloid leukemia, acute lymphoblastic leukemia and chronic myeloid leukemia, and they receive in total about 4 to 7 times of funds compared to those of the project team on adult leukemia in Japan which is supported by the Ministry of Health and Welfare and the official members of which are only up to 12 institutions. Through the present investigation, the reason why FRG has emerged as a super power in the field of clinical cancer study has become clear. FRG government has funded the clinical research as well as basic science in the war against cancer. In Japan, the 10-year war against cancer, which started in 1984, has funded almost exclusively basic research such as biotechnology. To establish high-standard clinical cancer study in Japan, more governmental funds should be distributed to clinical studies, at least to establish biostatistic centers which plan and control the clinical studies.

联邦德国（FRG）目前在白血病治疗领域处于世界领先地位。其强化治疗策略和参与全国临床研究的患者数量均超过美国。S.或欧洲其他地区。他们的白血病临床研究的质量和数量的迅速上升，得益于1979年开始的政府对抗癌战争的支持。他们的概念的特点是强调生物统计学在方案规划和数据分析中的作用，并在整个联邦德国建立了5个生物统计中心。不像在美国。S.联邦政府不支持成立肿瘤学小组，但针对每种癌症成立了项目小组。每个项目团队每年获得约20至50 x 10^6日元，为期约5至7年。例如，在成人白血病领域，有3个项目小组;急性髓性白血病、急性淋巴细胞白血病和慢性髓性白血病，它们总共获得的资金是日本成人白血病项目小组的4至7倍，后者由厚生省支持，其正式成员只有12个机构。通过目前的调查，FRG成为临床肿瘤研究领域的超级大国的原因已经变得清晰。联邦德国政府资助了临床研究以及基础科学在对抗癌症的战争。在日本，从1984年开始的十年抗癌战争几乎完全资助了生物技术等基础研究。为了在日本建立高标准的临床癌症研究，政府应将更多的资金分配给临床研究，至少建立计划和控制临床研究的生物统计中心。